Like! I'll take .53...
INVESTMENT SUMMARY
Prescient has sharpened its focus on lead anti-cancer compound PTX-200 and plans to add a Phase Ib trial in acute myeloid leukaemia (AML) to the ongoing Phase I/II trials in breast and ovarian cancers. It has raised ~A$2m through a share purchase plan and placement, which will fund operations until 2017. We raise our valuation to A$49m (A$0.53/share), with the addition of the AML indication for PTX-200 more than offsetting the deferral of Phase 1b trials for PTX-100.
- Forums
- ASX - By Stock
- PTX
- Ann: Edison Investment Research Initiates Coverage
Ann: Edison Investment Research Initiates Coverage, page-2
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PTX (ASX) to my watchlist
|
|||||
Last
4.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $32.21M |
Open | High | Low | Value | Volume |
4.0¢ | 4.1¢ | 4.0¢ | $3.084K | 76.05K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 261637 | 4.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
4.1¢ | 679528 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 261637 | 0.040 |
7 | 949434 | 0.039 |
10 | 1290788 | 0.038 |
3 | 130515 | 0.037 |
5 | 429500 | 0.036 |
Price($) | Vol. | No. |
---|---|---|
0.041 | 679528 | 4 |
0.042 | 350000 | 2 |
0.043 | 247971 | 2 |
0.044 | 210000 | 2 |
0.045 | 307000 | 2 |
Last trade - 10.53am 21/06/2024 (20 minute delay) ? |
Featured News
PTX (ASX) Chart |
The Watchlist
FHE
FRONTIER ENERGY LIMITED
Adam Kiley, CEO
Adam Kiley
CEO
Previous Video
Next Video
SPONSORED BY The Market Online